Latest Breaking News On - ஜூலியானே டார்ந் ப்ரொஃபெஸர் - Page 1 : comparemela.com

Share this article Share this article NEW YORK, Feb. 22, 2021 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evidence that FDA is seeking to support a Biologics License Application (BLA). In addition, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a BLA submission. 

United statesJudith pape adamsPaul tyahlaRobert brownCorey davisChaim lebovitsCalifornia institute for regenerative medicineBrainstorm cell therapeutics incLifesci advisorsUniversity of massachusetts medical schoolMayo clinic college of medicineDrug administrationHarvard medical schoolProgram in neurotherapeuticsPrnewswire brainstorm cell therapeutics incEuropean medicines agency